Price
$208.46+59.98%1Y
1M+3.01%1Y+59.98%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average7/10
Value42
Quality89
Momentum52
Growth25
P/E (TTM)21.4
Market Cap$29.02B
1Y Return+59.98%
5Y Return-48.99%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $3.35B (-5.35%)
●ZURZUVAE grew +99.64% YoY●TOFIDENCE -100.00% YoY
SegmentLatestQoQYoY
- MSProduct Revenues$559.4M-12.99%+14.07%
- Revenuesfromanticd20therapeuticprograms$419.1M-15.14%+10.81%
- Royalty Attributed To OCREVUS$317.2M-17.91%+9.83%
- Product And Service Other$246.9M+63.29%-15.82%
- Tysabri Product$241.8M-2.30%+20.42%
- Contract Manufacturing And Other Revenue$237.2M+67.63%-15.98%
- Rare Disease Product Revenue$224.5M-4.51%-2.81%
- Fumarate$184.8M-21.09%+17.78%
- VUMERITY$153.4M-19.09%+31.00%
- SPINRAZA$142.2M-7.18%-7.90%
- Interferon$132.8M-17.62%+0.08%
- AVONEX$108.5M-18.67%-0.09%
- SKYCLARYS$71.8M-3.75%+3.91%
- Alzheimers Collaboration$59.5M+39.34%+80.30%
- LEQEMBICollaboration$59.5M+39.34%+80.30%
- Other Products$55.3M0.00%+96.80%
- ZURZUVAE$55.3M0.00%+99.64%
- TECFIDERA$31.4M-29.60%-21.11%
- PLEGRIDY$24.3M-12.59%+0.83%
- QALSODY$10.5M+43.84%+40.00%
- Royalty$9.7M0.00%-11.82%
- ADUHELM---
- BENEPALI$0.00--
- BYOOVIZ$0.00-100.00%-100.00%
- Biosimilars$0.00-100.00%-100.00%
- FAMPYRA$0.00--
- FLIXABI$0.00--
- FUMADERMAnd ADUHELM$0.00--100.00%
- FUMADERM---
- IMRALDI$0.00--
- Othercorporaterevenues---
- Spinal Muscular Atrophy---
- TOFIDENCE$0.00--100.00%